US Patent Issued to PHARMABLOCK SCIENCES (NANJING) on Dec. 2 for "CBP/EP300 inhibitor and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,251, issued on Dec. 2, was assigned to PHARMABLOCK SCIENCES (NANJING) INC. (Jiangsu, China).

"CBP/EP300 inhibitor and use thereof" was invented by Lisha Wang (Jiangsu, China), Enge Zhang (Jiangsu, China) and Jin Li (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a compound represented by Formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a use thereof in preparing a drug for diseases mediated by CBP and/or EP300."

The patent was filed on April 25, 2021, under Application No. 17/920,890.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/...